TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01527721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Cross-Linking (CxL)
Description: The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Cross-Linking combined with t-PRK
Description: For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
Study: NCT03262376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Minerals + Vitamins
Description: A mineral and vitamin tablet
Study: NCT03134079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oatmeal
Description: Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oatmeal
Description: Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oatmeal
Description: Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
Study: NCT03262376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Minerals + Vitamins
Description: A mineral and vitamin tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Minerals + Vitamins
Description: A mineral and vitamin tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical A
Description: Botanical extract administered in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical A
Description: Botanical extract administered in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical B
Description: Botanical extract administered in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical B
Description: Botanical extract administered in capsule form

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose crystalline tablet
Study: NCT02284932

Intervention type: OTHER
Intervention: No specific intervention for this study
Description: No specific intervention for this study

Intervention type: OTHER
Intervention: No specific intervention for this study
Description: No specific intervention for this study
Study: NCT03673761

Intervention type: OTHER
Intervention: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing
Description: 3.Dixon, T2 mapping MRI microRNAs

Intervention type: OTHER
Intervention: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing
Description: 3.Dixon, T2 mapping MRI microRNAs

Intervention type: OTHER
Intervention: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing
Description: 3.Dixon, T2 mapping MRI microRNAs
Study: NCT03663166

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: 2 Gy in 30 fractions directed at all sites of suspected disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum Based Chemotherapy
Description: Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: ipilimumab 1mg/kg delivered concurrently with initiation of chemoradiotherapy and in week 4 of chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg (30 minute IV infusion) at least 7 days but no more than 21 days after completion of radiation and chemotherapy every 4 weeks for up to 12 cycles.
Study: NCT00682058

Intervention type: OTHER
Intervention: Follow-up post-bariatric surgery
Description: Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
Study: NCT02185378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: I:E ratio 1:2
Description: We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: I:E ratio 1:1
Description: The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
Study: NCT03554811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation assisted supine cycling (FESC)
Description: A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional early exercise and mobility interventions
Description: These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
Study: NCT04625777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Examen spiritual practice
Description: The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~1. Become aware of God's presence;~2. Give thanks to God for everything in your life;~3. Review the events of the day guided by the Holy Spirit;~4. Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~5. Look toward tomorrow - what one thing should you do? Listen to what God is telling you.
Study: NCT03499847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: advanced medical directive pamphlet
Description: A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
Study: NCT05733884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft contact lens
Description: soft contact lens

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: soft contact lens
Description: soft contact lens
Study: NCT04625777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress inoculation combination
Description: This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
Study: NCT01820715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600㎍ of DA-3030 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02762487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The LINX® Reflux Management System
Description: The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
Study: NCT01916278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Lips Lidocaine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderma Volbella with Lidocaine
Study: NCT03311672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-Ara-G
Description: Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-Ara-G
Description: Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
Study: NCT03447262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659/TEZ/IVA
Description: Fixed-dose combination tablets for oral administration qd in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA tablet qd in the evening.
Study: NCT01751594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE Intervention
Description: MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: H4L Comparison Intervention
Description: Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
Study: NCT01603862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ThinkingFit programme
Description: Combined physical, cognitive and social stimulation activties.
Study: NCT02493270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation therapy
Description: Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
Study: NCT03875755

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo Inositol
Description: One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
Study: NCT01258725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amnioinfusion procedure
Description: Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI\<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
Study: NCT03146130

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Variation of behaviors of Parkinson's disease
Description: Variation of hyper dopaminergic behaviors of Parkinson's disease

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Variation of behaviors of Parkinson's disease
Description: Variation of hyper dopaminergic behaviors of Parkinson's disease
Study: NCT00996788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide 100 mg tid for 28 days
Study: NCT03554811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional early exercise and mobility interventions
Description: These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
Study: NCT00717236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Description: 400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
Study: NCT02266264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
Study: NCT00717236

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
Study: NCT00824733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03512676
Description: Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
Study: NCT03311672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
Study: NCT04485455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS Device/Motor Threshold Coil
Description: Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS Device/Treatment Coil
Description: iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
Study: NCT02153099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 (ENV8058)
Description: TAK-058 (ENV8058) oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 (ENV8058)
Description: TAK-058 (ENV8058) oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 (ENV8058)
Description: TAK-058 (ENV8058) oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 (ENV8058)
Description: TAK-058 (ENV8058) oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 (ENV8058)
Description: TAK-058 (ENV8058) oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 (ENV8058)
Description: TAK-058 (ENV8058) oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-058 (ENV8058) placebo-matching oral solution
Study: NCT03972072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-defined MR-linac based IGRT and plan adaptation protocol
Description: daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: salivary flow measurements
Description: baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
Study: NCT03465033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Physiotherapy
Description: From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s.
Study: NCT00754156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABRA Abdominal Closure System
Description: ABRA Abdominal Closure System
Study: NCT00824733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
Study: NCT02771496

Intervention type: OTHER
Intervention: Other: observational only- no intervention
Description: Other: observational only- no intervention
Study: NCT02266264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
Study: NCT02970656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens.Connect
Description: Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
Study: NCT02640183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05213819

Intervention type: OTHER
Group type: OTHER
Intervention: Carpal Tunnel Syndrome